Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP972294priorityCriticalpatent/ECSP972294A/en
Publication of ECSP972294ApublicationCriticalpatent/ECSP972294A/en
Se describe una composición farmacéutica y un método para inhibir el virus de la inmunodeficiencia humana (VIH) el cual comprende administrar a un paciente infectado por VIH una combinación homogénea de lamivudina, zidovudina y un lubricante farmacéutico en una cantidad que logra eficacia antiviral.A pharmaceutical composition and method for inhibiting human immunodeficiency virus (HIV) is disclosed which comprises administering to an HIV-infected patient a homogeneous combination of lamivudine, zidovudine and a pharmaceutical lubricant in an amount that achieves antiviral efficacy.
AN EPO COMPOSITION, A PROCEDURE FOR OBTAINING IT, A PHARMACEUTICAL PREPARATION CONTAINING IT AND A PROCEDURE TO INCREASE THE SPECIFIC ACTIVITIES OF AN EPO COMPOSITION